In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.
about
Covariate pharmacokinetic model building in oncology and its potential clinical relevance.A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasIncorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor ImatinibInteractions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsPopulation pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumoursImatinib activity on Schistosoma mansoniPreclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.Prediction of Tissue-to-Plasma Ratios of Basic Compounds in Mice.Reduced exposure of imatinib after coadministration with acetaminophen in miceA pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responsePotent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
P2860
Q27687599-282D0822-120A-4AB4-9621-5713ED93BD71Q34063343-90BFA272-CA28-4680-8F04-2B4FD17FFE21Q34591403-9603CB8A-66D5-40FA-9742-633D032026E7Q34705820-64702F23-0A37-4EE2-82E3-1B16F7FFFCFDQ34714353-A3B28AE5-1743-4A91-A6ED-A5799CFA53C9Q35827125-76715442-6BD1-4CF7-90F1-EF5426F49816Q35827616-1AADC99A-E57C-4399-B086-B8FFFCE728EDQ35827640-923EBC5E-6CA5-48E2-A99B-7A0686624129Q35846126-39E468D0-AF97-4A90-8984-EA00A60BC28AQ36729934-590F9EE9-B163-414A-A919-E8643443E2F2Q37675128-7A489F3F-9254-40CC-873D-1D3A013DAEDCQ38045441-335E3244-F732-48D5-B504-DDD331CE3D31Q38724254-03CF79B1-650B-4AA1-942B-4BAF61C114F5Q38962990-9A1BD06E-7AD7-49E0-A807-B605C6C04B52Q40729511-E783C25D-D261-4437-A4CC-ED91E185536AQ42192063-90276462-5A13-43E0-9970-AAAC76B011AAQ42283688-999BE0FF-44FB-4F4E-8C7C-7E317CF7DD10Q43841175-373775D2-F447-48AF-94C9-990B6EE6CC9EQ45403481-7521C2A5-CE66-4C00-ADC4-A72D6FD372ADQ46431899-B3FF3290-D253-4E16-ACB6-7A5492F784C7Q55300020-34A01495-B45D-4840-8AA7-F99B152E255A
P2860
In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@ast
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@en
type
label
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@ast
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@en
prefLabel
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@ast
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@en
P2093
P2860
P1476
In vitro blood distribution an ...... ith acute lymphatic leukaemia.
@en
P2093
Gerhard Gross
H Markus Weiss
Martin M Schumacher
Olivier Kretz
P2860
P304
P356
10.1111/J.1365-2125.2004.02117.X
P407
P577
2004-08-01T00:00:00Z